Novo Nordisk (NVO) Hit With Investor Lawsuit Over Cagrisema Obesity Drug – Hagens Berman
The case, filed in the U.S. District Court for the District of New Jersey under the title Moon v. Novo Nordisk A/S, No. 25-cv-00713, alleges that the company and its key executives committed ...
FoodNavigator9h
A new generation of weight-loss drugs move beyond GLP-1
Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...
24/7 Wall St9h
HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?
The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...
Here is Why Novo Nordisk A/S (NVO) is Among the Most Oversold Pharma Stocks to Buy According to Analysts
We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to ...
abc7NY13h
Yearslong shortage of popular weight-loss and diabetes drugs is resolved, FDA says
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...